NEARLY half of patients reduce drinking following glucagon-like peptide-1 receptor agonist therapy, national survey results reveal. In a probability-based sample of 2,009 American adults, approximately 16% reported current or past use of these incretin mimetics, which are approved for type 2 diabetes and obesity. Among participants who consumed alcohol prior to treatment initiation, 44.2% documented a substantial or moderate decrease in their consumption during the first three months of therapy. An additional 52.6% experienced no change, while only 3.3% reported drinking more. With excessive alcohol consumption responsible for nearly 178,000 deaths annually across the United States, these patient-reported outcomes offer valuable clinical insights for preventive healthcare.
The reported decrease was markedly pronounced among individuals presenting with risky baseline consumption patterns. In the cohort screening positive for potentially unhealthy drinking on the single-item screening tool, 54.1% reported drinking less after beginning treatment. Multivariable logistic regression revealed that patients engaging in unhealthy drinking had more than double the odds of curbing intake compared to moderate drinkers (adjusted odds ratio, 2.30; 95% confidence interval, 1.20 to 4.42; P = .01). Notably, demographic variables such as age, sex, race, ethnicity, household income, and overall health status did not influence these outcomes.
These findings align with emerging mechanistic evidence indicating that incretin therapies modulate mesolimbic reward pathways and craving circuits in the brain. However, clinical understanding of GLP-1 receptor agonists and alcohol use remains underrecognized among the public. Only 9.7% of surveyed adults knew of this potential effect, compared to 79.3% recognizing weight reduction and 45.7% recognizing glycemic regulation. Awareness of the connection between GLP-1 receptor agonists and alcohol use was significantly higher among hazardous drinkers at 13.3%, yet overall recognition remains limited.
Investigators cautioned that the survey relied on retrospective self-reports, introducing possible recall and social desirability biases. Although large-scale randomized trials remain necessary to confirm definitive efficacy, mounting public interest could drive future clinical demand. Addressing this interest will require clinicians and policymakers to navigate existing insurance barriers and leverage telehealth access to manage care appropriately.
Reference
Uscher-Pines L et al. Patient-Reported Changes in Alcohol Use Following Glucagon-Like Peptide-1 Receptor Agonist Initiation. JAMA Psychiatry. 2026;doi:10.1001/jamapsychiatry.2026.3242.
Featured Image: metamorworks on Adobe Stock.
pavelkant on adobe stock
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
